Emerging immune-associated biomarkers in solid tumors

  • 274

    Total views and downloads

About this Research Topic

Submission deadlines

  1. Manuscript Summary Submission Deadline 3 September 2026 | Manuscript Submission Deadline 21 December 2026

  2. This Research Topic is currently accepting articles.

Background

In the era of personalized oncology, implementation of reliable biomarkers with prognostic and predictive value is necessary, the latter being most important with the introduction of immunotherapy as the backbone of treatment regimen in common solid tumors. Advancements in understanding tumor microenvironment (TME) has revealed immune-associated biomarkers with clinical significance. Assessment of tumor infiltrating lymphocytes including T cell cytotoxic lymphocytes in the TME has demonstrated prognostic impact in solid tumors, even though discrepancies among different studies pose a limitation in the translation to routine practice. Besides, evaluation of programmed death ligand 1 (PD-L1) is the main biomarker predicting response to immune-checkpoint inhibitors. However, PD-L1 status can be an unreliable biomarker. Hence, there is an unmet need to implement novel clinically reliable biomarkers, which will improve patient stratification and treatment efficacy.

The goal of this special issue is to improve our understanding of current and novel immune-associated biomarkers and demonstrate how these in turn could be implemented in daily practice. Introduction of novel immune-associated biomarkers is strongly associated with advancements in immune landscape both in primary lesions, as well as in metastatic lesions and peripheral circulation. Hence, a central objective of this issue includes studies that demonstrate the clinical value of immune-associated components, including immune cells or immune mediators (like chemokines and cytokines) in solid tumors. Along this line, we encourage studies that demonstrate the development of novel biomarkers with clinical value as well as studies that provide novel evidence for currently available biomarkers with prognostic and predictive value.

We welcome Original Research, Reviews, Mini Reviews, Systematic Reviews, Perspectives, Hypothesis & Theory, and Brief Research Reports focusing on the development of immune-associated biomarkers on solid tumors based on:

(1) spatial analysis, including single and multiplex in situ assays to study the spatial distribution and the corresponding clinical role of tumor infiltrating lymphocytes such as lymphocytes in different cell states (i.e. T cell exhaustion), tissue associated macrophages, druggable molecules (i.e. PD-L1, CD47) and mediators of inflammation (i.e. cytokines and chemokines)

(2) transcriptomic or proteomic analysis of tissue specimens along with integration of publicly available datasets

(3) immunophenotypic analysis of blood or body fluids

(4) mechanistic analysis



Biomarkers with prognostic and/or predictive value are equally valued.

Article types and fees

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

  • Brief Research Report
  • Case Report
  • Classification
  • Clinical Trial
  • Editorial
  • FAIR² Data
  • FAIR² DATA Direct Submission
  • General Commentary
  • Hypothesis and Theory

Articles that are accepted for publication by our external editors following rigorous peer review incur a publishing fee charged to Authors, institutions, or funders.

Keywords: biomarkers, prognosis, prediction, immune response, tumor microenvironment, circulation, immunophenotypic analysis

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Topic editors

Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.

Impact

  • 274Topic views
View impact